Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis

Table 1 Patient characteristics at index date, n (%)

Characteristic	Patients (N = 330)
Sex
Female	222 (67%)
Male	108 (33%)
Age at index
1–4 years	42 (13%)
5–9 years	77 (23%)
10–14 years	129 (39%)
15–17 years	82 (25%)
Indication*
Juvenile idiopathic arthritis	316 (96%)
Psoriatic arthritis	10 (3%)
Ankylosing spondylitis	3^† (1%)
Region
Quebec	118 (36%)
Ontario	110 (33%)
Alberta	50 (15%)
East	33 (10%)
British Columbia	15 (5%)
Prairies	3* (1%)
Payer
PDP	286 (87%)
OPDP	28 (8%)
RAMQ	16 (5%)

* Indications were inferred using an algorithm developed by IQVIA, which uses a patient’s drug history [7, 8, 30]
^†Groups with less than 6 patients/claims were adjusted to 3 to maintain privacy
PDP, IQVIA Private Drug Plan; OPDP, Ontario Public Drug Plans; RAMQ, Quebec Public Drug Plan, Régie de l’assurance maladie du Québec

ISSN: 1546-0096